Chan Tommy C Y, Kwok Peter S K, Jhanji Vishal, Woo Victor C P, Ng Alex L K
J Refract Surg. 2017 Jan 1;33(1):37-43. doi: 10.3928/1081597X-20161006-03.
To present the 1-year outcomes of combining monocular bi-aspheric ablation profile and contralateral monofocal LASIK in hyperopic patients with presbyopia.
In this retrospective case series, 36 consecutive patients (72 eyes) who underwent simultaneous bi-aspheric ablation (PresbyMAX: SCHWIND Eye-Tech-Solutions GmbH and Co KG, Kleinostheim, Germany) in the non-dominant eye and monofocal regular LASIK in the dominant eye for correction of hyperopia and presbyopia were reviewed for 1 year. Binocular uncorrected distance (UDVA), near (UNVA), corrected distance (CDVA), and distance corrected near (DCNVA) visual acuity and manifest refraction were analyzed postoperatively.
At 1 year, the mean binocular UDVA improved significantly from 0.26 ± 0.25 to 0.039 ± 0.088 logMAR (P < .001). Binocular UNVA also improved from 0.73 ± 0.30 to 0.10 ± 0.22 logRAD (P < .001). Eighty-seven percent of patients achieved UDVA of 20/25 or better and 90% had UNVA of J3 or better. Simultaneous binocular distance and near vision of 20/25 and J2 or better was achieved in 70%. Only 17% of patients had a binocular DCNVA of J2 or better. No patient suffered from a loss of 2 lines of CDVA. Refractive stability was achieved for both eyes from 1 month postoperatively. The re-treatment rate was 14% for improvement of near vision within 6 months to 1 year.
Presbyopic correction using monocular PresbyMAX combined with monofocal regular LASIK in the fellow eye is safe and acceptable in hyperopic patients. [J Refract Surg. 2017;33(1):37-43.].
介绍在患有老花眼的远视患者中,单眼双非球面消融轮廓与对侧单焦点准分子原位角膜磨镶术(LASIK)联合治疗的1年效果。
在这个回顾性病例系列中,对36例连续患者(72只眼)进行了为期1年的回顾,这些患者非主眼接受同步双非球面消融(PresbyMAX:德国施温德眼科技术解决方案有限公司,克莱诺施泰姆),主眼接受单焦点常规LASIK,用于矫正远视和老花眼。术后分析双眼未矫正远视力(UDVA)、近视力(UNVA)、矫正远视力(CDVA)以及矫正远距近视力(DCNVA)和明显屈光不正。
1年后,双眼平均UDVA从0.26±0.25显著提高至0.(此处原文可能有误,推测应为)039±0.088 logMAR(P<.001)。双眼UNVA也从0.73±0.30提高至0.10±0.22 logRAD(P<.001)。87%的患者达到20/25或更好的UDVA,90%的患者达到J3或更好的UNVA。70%的患者同时实现了20/25及以上的双眼远视力和J2或更好的近视力。只有17%的患者双眼DCNVA达到J2或更好。没有患者CDVA下降2行。术后1个月双眼均实现屈光稳定。6个月至1年内近视力改善的再治疗率为14%。
在远视患者中,单眼使用PresbyMAX联合对侧眼单焦点常规LASIK进行老花眼矫正安全且可接受。[《屈光手术杂志》。2017;33(1):37 - 43。]